Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
06 August 2020

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Sun Pharmaceuticals Industries Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 532.25
Net Changes 3.40
Volume 10920296
Prev Close 528.85
532.25 3.40 (0.64%)
Date: Aug 06,2020 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 532.65 Div Yield (%) 0.75
Buy (Size) 532.20(×174) Eps(Rs) 12.42
Sell (Size) 532.20(×291) Book Value (Stand.)(Rs) 101.68
Value 21012381200 Book Value(conso.)(Rs) 188.6541649
Buy Quantity 174 Market Cap(Rs.Cr) 127692.61
Sell Quantity 291 Face Value(Rs) 1
Today's High 541 Market Lot 1
Today's Low 526.35 AGM Date Aug
52-Week High 541 Book Closure Date Aug
52-Week Low 315.2 ISIN No. INE044A01036

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 1312134535 54.69
Total of Promoter 1312134535 54.69
Non Promoter (Institution) 787134705 32.81
Non Promoter (Non-Institution) 300065730 12.51
Total Non Promoter 1087200435 45.31
Total Promoter & Non Promoter 2399334970 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 2399334970 100.00

Company News

05-Aug-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on August 04, 2020. Total no. of equity shares bought back are 0
04-Aug-2020  Sun Pharma launches FluGuard®, an oral anti-viral treatment fo...
Sun Pharma launches FluGuard®, an oral anti-viral treatment for COVID-19 treatment

Sun Pharmaceutical Industries announced that it has launched FluGuard® (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The company will work closely with the government and medical community to ensure availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.

FluGuard® is the registered trade mark of Sun Pharma.

04-Aug-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Shareholders meeting

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2020
03-Aug-2020  Sun Pharma announced completion of acquisition of Aquinox Phar...
Sun Pharma announced completion of acquisition of Aquinox Pharmaceuticals (Canada)

Sun Pharmaceutical Industries announced that Taro Pharmaceuticals Inc. (subsidiary of Taro Pharmaceutical Industries) has on 31 July 2020 completed the acquisition of all shares of Aquinox Pharmaceuticals (Canada) Inc. by making the payment of USD $8.2Mn and complying all requirements.
03-Aug-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Updates

Sun Pharmaceutical Industries Limited has informed the Exchange regarding Update on Acquisition.
01-Aug-2020  Sun Pharmaceuticals Industries AGM scheduled
Sun Pharmaceuticals Industries AGM scheduled

Sun Pharmaceuticals Industries announced that the 28th Annual General Meeting (AGM) of the company will be held on 27 August 2020.
31-Jul-2020  Sun Pharma records Q1 net loss of Rs 1656 cr
Sun Pharma records Q1 net loss of Rs 1656 cr

Net sales declined 9.6% on a year-on-year (YoY) basis to Rs 7,467.19 crore in the first quarter of the financial year 2020-21. Research and development expenses rose 2.1% YoY to Rs 415.19 crore in Q1 June 2020.

Profit before tax and exceptional items fell 12% to Rs 1,449.43 crore in Q1 FY21 from Rs 1,647.44 crore in Q1 FY20.

The company recorded an exceptional expenditure of Rs 3,633.33 crore during the quarter ended 30 June 2020 on account of settlement of civil antitrust matters by Taro Pharmaceuticals U.S.A., Inc., Sun Pharma's subsidiary, with the United States' Department of Justice and certain other provisions relating to the same.

Pre-tax loss in Q1 FY21 stood at Rs 2,183.90 crore as against a pre-tax profit of Rs 1,647.44 recorded in the same period last year.

Tax expenses for the June quarter increased by 68.4% to Rs 245.91 crore compared with Rs 146.06 crore incurred in Q1 June 2019.

Meanwhile, the drug major's board approved the scheme of amalgamation and merger between the company and Sun Pharma Global FZE (wholly owned subsidiary of the company). It envisages merger of Sun Pharma Global FZE into the company. The scheme shall be effective post receipt of required approvals and accordingly, the above results do not reflect the impact on account of the scheme, Sun Pharma said.

'The combined entity will have a bigger portfolio of products and direct access to markets, which will strengthen its capabilities to serve more efficiently its customers. This will also enable the SPIL address the competitive regulatory environment, risks and policies, better management of supply chain, better product profiling, greater differentiation, ability to strategize the Business for long term growth', the company said in a statement.

Shares of Sun Pharma jumped 4.27% to Rs 531.75 on Friday. It traded in the range of 507.75 and 540.75 during the day.

Sun Pharmaceutical Industries is a specialty generic manufacturing pharma company.

31-Jul-2020  Board of Sun Pharma has approved scheme of amalgamation and me...
Board of Sun Pharma has approved scheme of amalgamation and merger

The Board of Sun Pharmaceutical Industries at its meeting held on 31 July 2020 has approved the scheme of Amalgamation and Merger of Sun Pharma Global FZE (“Transferor Company”), an indirect wholly owned subsidiary of the Company with Sun Pharmaceutical Industries ('Transferee Company' or “Company”) and their respective members and creditors (“Scheme”) pursuant to Section 234 read with Sections 230 to 232 of the Companies Act, 2013 and the relevant rules and regulations made thereunder for amalgamation of Transferor Company into the Company subject to receipt of necessary approvals of the Hon'ble National Company Law Tribunal at Ahmedabad and all other requisite parties/authorities as may be required to give effect to the Scheme.
30-Jul-2020  Sun Pharmaceuticals Industries Ltd soars 1.24%, Gains for thir...
Sun Pharmaceuticals Industries Ltd soars 1.24%, Gains for third straight session

Sun Pharmaceuticals Industries Ltd is up for a third straight session in a row. The stock is quoting at Rs 499.1, up 1.24% on the day as on 12:54 IST on the NSE. The benchmark NIFTY is up around 0.24% on the day, quoting at 11230.2. The Sensex is at 38104.54, up 0.09%. Sun Pharmaceuticals Industries Ltd has added around 6.61% in last one month.

Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has added around 8.42% in last one month and is currently quoting at 10441.15, up 2.62% on the day. The volume in the stock stood at 88.74 lakh shares today, compared to the daily average of 81.82 lakh shares in last one month.

The benchmark July futures contract for the stock is quoting at Rs 498.8, up 0.9% on the day. Sun Pharmaceuticals Industries Ltd is up 16.95% in last one year as compared to a 1.01% gain in NIFTY and a 34.14% gain in the Nifty Pharma index.

The PE of the stock is 36.85 based on TTM earnings ending March 20.

30-Jul-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on July 29, 2020. Total no. of equity shares bought back are 0
Incorporation Year 1993 
Registered Office Sun Pharma Advanced Res.Centre,Tandalja,
Vadodara,
Gujarat-390020
Telephone 91-265-6615500 
Fax 91-265-2354897 
Chairman Israel Makov
Managing Director Dilip S Shanghvi
Company Secretary Sunil R Ajmera 
Auditor S R B C & Co LLP 
Face Value(Rs)
Market Lot
Listing BSE,MSEI,NSE 
Registrar Link Intime India Pvt Ltd
C-101 247 Park,L B S Marg,Vikhroli West,Mumbai-400083 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS